Our Vision


To improve cancer patient outcomes by developing
advanced oncology diagnostics.

Clinical Need

Circulating Tumor Cells are robust biomarkers that may help oncologists make more informed cancer treatment decisions. Currently available CTC capture technologies may not be sensitive enough to realize the full potential of CTCs. Early data using our CapioCyte technology with clinical samples has shown very promising results 


An innovative and ultra-sensitive
technology for the capture and analysis of CTCs from whole blood

Greater Sensitivity

Our clinical data show a sensitivity of up to
10 to 100 times greater
than previously published data using other currently available platforms.
This enhanced sensitivity makes the CapioCyte platform an excellent tool for cancer research,
and potential clinical use in the future.

Need more details? Contact us.


We are here to assist. If you require further information or are interested in collaborations or partnerships, contact us by phone, email or via our social media channels.

  • White LinkedIn Icon
  • White Twitter Icon
  • White Facebook Icon

505 S. Rosa Road
Suite 10C
Madison, WI 53719


* The CapioCyte System is currently under development and not for use in diagnostic procedures.


Capio and CapioCyte are trademarks of Capio Biosciences.